These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 32512272)

  • 1. Durvalumab vs placebo consolidation therapy after chemoradiotherapy in stage III non-small-cell lung cancer: An updated PACIFIC trial-based cost-effectiveness analysis.
    Han J; Tian K; Yang J; Gong Y
    Lung Cancer; 2020 Aug; 146():42-49. PubMed ID: 32512272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. International Cost-Effectiveness Analysis of Durvalumab in Stage III Non-Small Cell Lung Cancer.
    Kareff SA; Han S; Haaland B; Jani CJ; Kohli R; Aguiar PN; Huang Y; Soo RA; Rodríguez-Perez Á; García-Foncillas J; Dómine M; de Lima Lopes G
    JAMA Netw Open; 2024 May; 7(5):e2413938. PubMed ID: 38814640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Durvalumab consolidation therapy in patients with stage III non-small cell lung cancer after concurrent chemoradiation: a China-based cost-effectiveness analysis.
    Chen X; Yang Z; Xiang G; Gu L; Qi Z; Wan B; Lu Y; Chang F; Zhu Y
    Expert Rev Pharmacoecon Outcomes Res; 2022 Jun; 22(4):647-654. PubMed ID: 34643129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness and Net Monetary Benefit of Durvalumab Consolidation Therapy Versus No Consolidation Therapy After Chemoradiotherapy in Stage III Non-small Cell Lung Cancer in the Italian National Health Service.
    Armeni P; Borsoi L; Fornaro G; Jommi C; Grossi F; Costa F
    Clin Ther; 2020 May; 42(5):830-847. PubMed ID: 32354495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cost-effectiveness analysis of consolidation immunotherapy with durvalumab in stage III NSCLC responding to definitive radiochemotherapy in Switzerland.
    Panje CM; Lupatsch JE; Barbier M; Pardo E; Lorez M; Dedes KJ; Aebersold DM; Plasswilm L; Gautschi O; Schwenkglenks M;
    Ann Oncol; 2020 Apr; 31(4):501-506. PubMed ID: 32107097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System.
    Criss SD; Mooradian MJ; Sheehan DF; Zubiri L; Lumish MA; Gainor JF; Reynolds KL; Kong CY
    JAMA Oncol; 2019 Mar; 5(3):358-365. PubMed ID: 30543349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analyses of durvalumab consolidation therapy versus no consolidation therapy after chemoradiotherapy in stage-III NSCLC.
    Hussain S; Klugarova J; Klugar M
    Lung Cancer; 2022 Aug; 170():11-19. PubMed ID: 35691134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost Effectiveness of Durvalumab in Unresectable Stage III NSCLC: 4-Year Survival Update and Model Validation from a UK Healthcare Perspective.
    Dunlop W; van Keep M; Elroy P; Perez ID; Ouwens MJNM; Sarbajna T; Zhang Y; Greystoke A
    Pharmacoecon Open; 2022 Mar; 6(2):241-252. PubMed ID: 34532842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness of Durvalumab After Chemoradiotherapy in Unresectable Stage III NSCLC: A US Healthcare Perspective.
    Mehra R; Yong C; Seal B; van Keep M; Raad A; Zhang Y
    J Natl Compr Canc Netw; 2021 Feb; 19(2):153-162. PubMed ID: 33545688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-Line Durvalumab in Addition to Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer: A U.S.-Based Cost-Effectiveness Analysis.
    Lin S; Luo S; Gu D; Li M; Rao X; Wang C; Huang P; Xu X; Weng X
    Oncologist; 2021 Nov; 26(11):e2013-e2020. PubMed ID: 34431578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness Analysis of Atezolizumab Versus Durvalumab as First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer in the USA.
    Ionova Y; Vuong W; Sandoval O; Fong J; Vu V; Zhong L; Wilson L
    Clin Drug Investig; 2022 Jun; 42(6):491-500. PubMed ID: 35604530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of durvalumab plus etoposide: platinum in the first-line therapy of extensive stage small-cell lung cancer from the Chinese payers' perspective.
    Tong YH; Ding HY; Xin WX; Zhong LK; Xu GQ; Zhang B; Yang GN; Fang L
    Tumori; 2022 Feb; 108(1):33-39. PubMed ID: 33511911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
    Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P
    Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness Analysis of Cemiplimab Versus Chemotherapy as First-Line Treatment in Advanced NSCLC with PD-L1 Expression Levels of at Least 50.
    Wang L; Peng Y; Zeng X; Peng L; Li S; Qin S; Wan X; Tan C
    Adv Ther; 2021 Aug; 38(8):4354-4365. PubMed ID: 34241780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non-Small-Cell Lung Cancer (PACIFIC).
    Socinski MA; Özgüroğlu M; Villegas A; Daniel D; Vicente D; Murakami S; Hui R; Gray JE; Park K; Vincent M; Mann H; Newton M; Dennis PA; Antonia SJ
    Clin Lung Cancer; 2021 Nov; 22(6):549-561. PubMed ID: 34294595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line tremelimumab plus durvalumab and chemotherapy
    Liu W; Huo G; Chen P
    Front Pharmacol; 2023; 14():1163381. PubMed ID: 37547328
    [No Abstract]   [Full Text] [Related]  

  • 17. Budget impact analysis of durvalumab consolidation therapy vs no consolidation therapy after chemoradiotherapy in stage III non-small cell lung cancer in the context of the Chilean health care system.
    Armijo N; Salas C; Espinoza N; Espinoza M; Balmaceda C
    PLoS One; 2024; 19(7):e0307473. PubMed ID: 39058755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer.
    Ding D; Hu H; Liao M; Shi Y; She L; Yao L; Zhu Y; Zeng S; Huang J
    Adv Ther; 2020 May; 37(5):2116-2126. PubMed ID: 32193809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A trial-based cost-utility analysis of sugemalimab vs. placebo as consolidation therapy for unresectable stage III NSCLC in China.
    Li W; Wan L
    PLoS One; 2023; 18(6):e0286595. PubMed ID: 37262075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of durvalumab as a maintenance treatment for patients with locally advanced, unresectable, stage Ⅲ nsclc in china.
    Jiang X; Chen J; Zheng M; Jia H
    PLoS One; 2022; 17(6):e0270118. PubMed ID: 35749385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.